

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

INSIDE INFORMATION — UPDATED INFORMATION IN RELATION TO THE UNVERIFIED LIST

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement of the Company dated February 8, 2022 (the “**Announcement**”) in relation to the decision of the U.S. Commerce Department to include the Subsidiaries to the Unverified List. Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as defined in the Announcement.

The Company is pleased to announce that on October 7, 2022, one of its subsidiaries, WuXi Biologics Co., Ltd., has been removed from the Unverified List by the U.S. Commerce Department following successful completion of the on-site end-use check visit by the U.S. Commerce Department, in coordination with China’s Ministry of Commerce. The Company remains committed to working with the relevant government agencies to remove its other subsidiary, WuXi Biologics (Shanghai) Co., Ltd., from the Unverified List. The Group has always been committed to operating with the highest standard of compliance and in accordance with relevant laws and regulations. The Group will continue to enable the biopharma and biotech partners in the benefits of the patients worldwide, and has the full confidence in strong growth prospects.

The Company will make further announcements as and when appropriate in accordance with the Listing Rules and the SFO in the event of any material development of the above matter.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, October 10, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*